tetano
Editor, Senior Moderator
PLoS One
. 2025 May 13;20(5):e0321511.
doi: 10.1371/journal.pone.0321511. eCollection 2025. Efficacy of BCG vaccination against COVID-19 in health care workers and non-health care workers: A meta-analysis of randomized controlled trials
Zhuoyang Xia[SUP] 1 2 [/SUP], Jiahao Meng[SUP] 1 3 [/SUP], Xuanyu Wang[SUP] 1 2 [/SUP], Pan Liu[SUP] 1 [/SUP], Yumei Wu[SUP] 1 [/SUP], Yilin Xiong[SUP] 1 [/SUP], Baimei He[SUP] 4 5 [/SUP], Shuguang Gao[SUP] 1 3 4 [/SUP]
Affiliations
Background: The Bacillus Calmette-Guérin (BCG) vaccine has shown potential non-specific protection against infectious diseases through "trained immunity", which may offer cross-protection against viral infections. However, there is no consensus on whether BCG vaccination could prevent COVID-19 or reduce its symptoms.
Methods: PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials on BCG vaccination and COVID-19 prevention, covering studies from the inception of each database to 2 May 2024. We included studies where participants, not infected with COVID-19, were vaccinated with BCG or placebo. We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. Clinical data on COVID-19 infection, severity, hospitalization, mortality, and other adverse events, were extracted and analyzed. The DerSimonian-Laird random-effects model and the Cochrane Collaboration's risk of Bias Tool were used for analysis and risk of bias assessment.
Results: A total of 12 RCTs involving 18,086 patients were finally included. For the prophylactic effect of BCG on COVID-19, pooled results showed no statistically significant difference between BCG and placebo (pooled RR 1.02; 95%CI: 0.91-1.14). There was no statistically significant difference between non-health care workers (pooled RR 0.91; 95%CI: 0.67-1.24) and health care workers (pooled RR 1.03; 95%CI: 0.93-1.15). Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81-1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84-1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92-1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58-1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18-1.95) between BCG and placebo groups. Subgroup analysis also showed no significant difference between BCG and placebo in non-health care workers or health care workers.
Conclusions: Vaccination of BCG could not effectively prevent COVID-19 infection or decrease COVID-19 symptoms both in non-health care workers and health care workers.
. 2025 May 13;20(5):e0321511.
doi: 10.1371/journal.pone.0321511. eCollection 2025. Efficacy of BCG vaccination against COVID-19 in health care workers and non-health care workers: A meta-analysis of randomized controlled trials
Zhuoyang Xia[SUP] 1 2 [/SUP], Jiahao Meng[SUP] 1 3 [/SUP], Xuanyu Wang[SUP] 1 2 [/SUP], Pan Liu[SUP] 1 [/SUP], Yumei Wu[SUP] 1 [/SUP], Yilin Xiong[SUP] 1 [/SUP], Baimei He[SUP] 4 5 [/SUP], Shuguang Gao[SUP] 1 3 4 [/SUP]
Affiliations
- PMID: 40359420
- PMCID: PMC12074600
- DOI: 10.1371/journal.pone.0321511
Background: The Bacillus Calmette-Guérin (BCG) vaccine has shown potential non-specific protection against infectious diseases through "trained immunity", which may offer cross-protection against viral infections. However, there is no consensus on whether BCG vaccination could prevent COVID-19 or reduce its symptoms.
Methods: PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials on BCG vaccination and COVID-19 prevention, covering studies from the inception of each database to 2 May 2024. We included studies where participants, not infected with COVID-19, were vaccinated with BCG or placebo. We excluded non-randomized trials, studies without full texts, unrelated interventions, and those not reporting relevant outcomes. Clinical data on COVID-19 infection, severity, hospitalization, mortality, and other adverse events, were extracted and analyzed. The DerSimonian-Laird random-effects model and the Cochrane Collaboration's risk of Bias Tool were used for analysis and risk of bias assessment.
Results: A total of 12 RCTs involving 18,086 patients were finally included. For the prophylactic effect of BCG on COVID-19, pooled results showed no statistically significant difference between BCG and placebo (pooled RR 1.02; 95%CI: 0.91-1.14). There was no statistically significant difference between non-health care workers (pooled RR 0.91; 95%CI: 0.67-1.24) and health care workers (pooled RR 1.03; 95%CI: 0.93-1.15). Regarding COVID-19 severity, no significant difference were found for asymptomatic (pooled RR 1.18; 95%CI: 0.81-1.72), mild to moderate (pooled RR 0.99; 95%CI: 0.84-1.17), severe COVID-19 (pooled RR 1.25; 95%CI: 0.92-1.70), hospitalization (pooled RR 0.93; 95%CI: 0.58-1.50) or all-cause mortality (pooled RR 0.60; 95%CI: 0.18-1.95) between BCG and placebo groups. Subgroup analysis also showed no significant difference between BCG and placebo in non-health care workers or health care workers.
Conclusions: Vaccination of BCG could not effectively prevent COVID-19 infection or decrease COVID-19 symptoms both in non-health care workers and health care workers.